Clinical Implications of Switching Lipid Lowering Treatment from Rosuvastatin to Other Agents in Primary Care

ConclusionWe conclude that switching from rosuvastatin to another non-equipotent LLT may impart an increased risk of AMI and should be avoided.FundingAstraZeneca SpA.

http://link.springer.com/10.1007/s12325-016-0412-8

Source: Advances in Therapy - September 25, 2016 Category: Drugs & Pharmacology Source Type: research